Clinical Trial Update: Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating immune globulin plus rituximab for desensitization in highly HLA-sensitized patients awaiting deceased donor kidney transplantation; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Rituximab (rituximab)
• immune globulin (immunoglobulin)

Snippet

Sponsor: Stanley Jordan, MD | Conditions: End Stage Renal Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-09-07